Cell Therapeutics (CTIC): Q2 EPS of -$0.28. As of June 30, the company had ~$14.8M in cash and...

|About: CTI BioPharma Corp. (CTIC)|By:, SA News Editor
Cell Therapeutics (CTIC): Q2 EPS of -$0.28. As of June 30, the company had ~$14.8M in cash and cash equivalents. European launch of Pixuvri is targeted for Q4. Steven E. Benner named Chief Medical Officer. Targets cut in net operating burn rate to an average of $4.5M/month for the rest of 2012 from $6.5M/month. (PR)